scispace - formally typeset
Search or ask a question
Topic

Near-Infrared Fluorescence Imaging

About: Near-Infrared Fluorescence Imaging is a research topic. Over the lifetime, 364 publications have been published within this topic receiving 13324 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: This review focuses on those parameters that affect image signal and background during in vivo imaging with near-infrared light and exogenous contrast agents.

2,470 citations

Journal ArticleDOI
18 Jan 2011-ACS Nano
TL;DR: This novel multifunctional nanomedicine may be useful for near-infrared fluorescence imaging and PTT/PDT in various cancers.
Abstract: A gold nanorod (GNR)−photosensitizer complex was developed for noninvasive near-infrared fluorescence imaging and cancer therapy. We showed that (a) fluorescence emission and singlet oxygen generation by AlPcS4 were quenched after complex formation with GNRs; (b) 4-fold greater intracellular uptake and better in vitro phototoxicity were observed in GNR−AlPcS4-treated cells than in free AlPcS4-treated cells; and (c) after intravenous injection of the GNR−AlPcS4 complex, tumor sites were clearly identified on near-infrared fluorescence images as early as 1 h after injection. The tumor-to-background ratio increased over time and was 3.7 at 24 h; tumor growth reduced by 79% with photodynamic therapy (PDT) alone and by 95% with dual photothermal therapy (PTT) and PDT. This novel multifunctional nanomedicine may be useful for near-infrared fluorescence imaging and PTT/PDT in various cancers.

706 citations

Journal ArticleDOI
TL;DR: Simultaneous pan-lymphatic and SLN mapping was demonstrated in swine using clinically available NIR fluorophores and the dual NIR capabilities of the FLARE™ system, describing the successful clinical translation of a new NIR fluorescence imaging system for image-guided oncologic surgery.
Abstract: Background Invisible NIR fluorescent light can provide high sensitivity, high-resolution, and real-time image-guidance during oncologic surgery, but imaging systems that are presently available do not display this invisible light in the context of surgical anatomy. The FLARE™ imaging system overcomes this major obstacle.

663 citations

Journal ArticleDOI
Weibo Cai1, Kai Chen1, Zibo Li1, Sanjiv S. Gambhir1, Xiaoyuan Chen1 
TL;DR: Histologic examination revealed that DOTA–QD–RGD targets primarily the tumor vasculature through an RGD–integrin αvβ3 interaction, with little extravasation.
Abstract: To date, the in vivo imaging of quantum dots (QDs) has been mostly qualitative or semiquantitative. The development of a dual-function PET/near-infrared fluorescence (NIRF) probe can allow for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. Methods: A QD with an amine-functionalized surface was modified with RGD peptides and 1,4,7,10-tetraazacyclodocecane-N,N′,N″,N‴-tetraacetic acid (DOTA) chelators for integrin αvβ3–targeted PET/NIRF imaging. A cell-binding assay and fluorescence cell staining were performed with U87MG human glioblastoma cells (integrin αvβ3–positive). PET/NIRF imaging, tissue homogenate fluorescence measurement, and immunofluorescence staining were performed with U87MG tumor–bearing mice to quantify the probe uptake in the tumor and major organs. Results: There are about 90 RGD peptides per QD particle, and DOTA–QD–RGD exhibited integrin αvβ3–specific binding in cell cultures. The U87MG tumor uptake of 64Cu-labeled DOTA–QD was less than 1 percentage injected dose per gram (%ID/g), significantly lower than that of 64Cu-labeled DOTA–QD–RGD (2.2 ± 0.3 [mean ± SD] and 4.0 ± 1.0 %ID/g at 5 and 18 h after injection, respectively; n = 3). Taking into account all measurements, the liver-, spleen-, and kidney-to-muscle ratios for 64Cu-labeled DOTA–QD–RGD were about 100:1, 40:1, and 1:1, respectively. On the basis of the PET results, the U87MG tumor-to-muscle ratios for DOTA–QD–RGD and DOTA–QD were about 4:1 and 1:1, respectively. Excellent linear correlation was obtained between the results measured by in vivo PET imaging and those measured by ex vivo NIRF imaging and tissue homogenate fluorescence (r2 = 0.93). Histologic examination revealed that DOTA–QD–RGD targets primarily the tumor vasculature through an RGD–integrin αvβ3 interaction, with little extravasation. Conclusion: We quantitatively evaluated the tumor-targeting efficacy of a dual-function QD-based probe with PET and NIRF imaging. This dual-function probe has significantly reduced potential toxicity and overcomes the tissue penetration limitation of optical imaging, allowing for quantitative targeted imaging in deep tissue.

400 citations

Journal ArticleDOI
TL;DR: In this article, the integrin receptor specificity of novel peptide-dye conjugate arginine-glycine-aspartic acid (RGD)-Cy5.5 was reported.
Abstract: Noninvasive visualization of cell adhesion molecule alpha(v)beta(3) integrin expression in vivo has been well studied by using the radionuclide imaging modalities in various preclinical tumor models. A literature survey indicated no previous use of cyanine dyes as contrast agents for in vivo optical detection of tumor integrin. Herein, we report the integrin receptor specificity of novel peptide-dye conjugate arginine-glycine-aspartic acid (RGD)-Cy5.5 as a contrast agent in vitro, in vivo, and ex vivo. The RGD-Cy5.5 exhibited intermediate affinity for alpha(v)beta(3) integrin (IC(50) = 58.1 +/- 5.6 nmol/L). The conjugate led to elevated cell-associated fluorescence on integrin-expressing tumor cells and endothelial cells and produced minimal cell fluorescence when coincubated with c(RGDyK). In vivo imaging with a prototype three-dimensional small-animal imaging system visualized subcutaneous U87MG glioblastoma xenograft with a broad range of concentrations of fluorescent probe administered via the tail vein. The intermediate dose (0.5 nmol) produces better tumor contrast than high dose (3 nmol) and low dose (0.1 nmol) during 30 minutes to 24 hours postinjection, because of partial self-inhibition of receptor-specific tumor uptake at high dose and the presence of significant amount of background fluorescence at low dose, respectively. The tumor contrast was also dependent on the mouse viewing angles. Tumor uptake of RGD-Cy5.5 was blocked by unlabeled c(RGDyK). This study suggests that the combination of the specificity of RGD peptide/integrin interaction with near-infrared fluorescence detection may be applied to noninvasive imaging of integrin expression and monitoring anti-integrin treatment efficacy providing near real-time measurements.

354 citations


Network Information
Related Topics (5)
Cancer cell
93.4K papers, 3.5M citations
75% related
Metastasis
103.6K papers, 3.4M citations
72% related
Prostate cancer
88.6K papers, 2.8M citations
72% related
Cancer
339.6K papers, 10.9M citations
71% related
Angiogenesis
58.2K papers, 3.2M citations
71% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202134
202029
201929
201839
201730
201631